Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04807517 · ClinicalTrials.gov registry record · Phase 4
Buspirone Treatment of Anxiety in Williams Syndrome
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04807517: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT04807517 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04807517, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to do a preliminary assessment of whether buspirone is effective, safe, and tolerable in the treatment of anxiety in children, adolescents, and adults with Williams syndrome.
Interventions
- DRUG Buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2023-09-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04807517
The ClinicalTrials.gov registry entry for NCT04807517 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buspirone is the first listed.
NCT04807517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04807517 about?
NCT04807517 is a clinical study titled "Buspirone Treatment of Anxiety in Williams Syndrome". The purpose of this study is to do a preliminary assessment of whether buspirone is effective, safe, and tolerable in the treatment of anxiety in children, adolescents, and adults with Williams syndrome.
What is the current status of trial NCT04807517?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2021-08-01. Estimated completion is 2023-09-11.
What interventions are being tested in trial NCT04807517?
The interventions under investigation include: Buspirone (DRUG).
Who is sponsoring clinical trial NCT04807517?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.